Bayban’s GSK GSK Stock Holding History

Bayban’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.7K	Hold	1,273	–	–	0.05%	208
2026 Q1	$70.3K	Hold	1,273	–	–	0.06%	204
2025 Q4	$62.4K	Buy	+1,273	New	+$59.4K	0.06%	206

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayban's GSK Position: Q2 2026 in Review

Bayban held its GSK (GSK) position steady in Q2 2026 at 1,273 shares worth $66.7K. The position accounts for 0.05% of the portfolio, ranked #208.

Bayban first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. The position peaked at $70.3K in Q1 2026. 999 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bayban held 1,273 shares of GSK worth $66.7K as of Q2 2026.
Bayban left its GSK share count unchanged in Q2 2026.
GSK made up 0.05% of Bayban's portfolio in Q2 2026, its #208 holding.
Bayban first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
Bayban's GSK position peaked at $70.3K in Q1 2026.
999 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.